Navigation Links
Combination HPV diagnostic test for head and neck cancer outperformed other tests
Date:10/2/2011

Philadelphia -- Researchers have determined that a combination of P16 immunohistochemistry and DNA qPCR to test for viral E6 can accurately determine the oropharyngeal squamous cell carcinoma, a form of head and neck cancer, which derive from HPV16, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

"This has immediate clinical applications as we consider recruitment to clinical trials designed to de-escalate the intensity of therapy based on HPV status" said lead researcher Andrew Schache, D.D.S., M.D., research fellow and surgeon at the University of Liverpool.

Schache said that the attention surrounding HPV, particularly in the last several years, has given rise to a number of diagnostic tests, but the evaluation of these tests has lagged behind.

For the current study, Schache and colleagues evaluated eight possible combinations of known diagnostic tests on 108 cases of HPV16 derived oropharyngeal squamous cell carcinoma. They used viral gene expression as the standard marker.

"Viral gene expression has 100 percent specificity and sensitivity, but it requires very high quality tissue that is often not available," said Schache.

After evaluating the tests, they found that a combination of DNA qPCR and P16 immunohistochemistry had 97 percent sensitivity, a measure of accurate positive tests, and 94 percent specificity, a measure of accurate negative tests.

Both of these assays are commercially available in proprietary and generic forms, Schache said, so the combination test could be administered.

"Getting the diagnosis right is extremely important because cases like this may receive less aggressive therapy based on a positive test. You do not want to withhold treatment from a more aggressive case," he said.


'/>"/>
Contact: Jeremy Moore
Jeremy.Moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

0

GOOD

Page: 1

Related biology news :

1. Novel drug combination offers therapeutic promise for hard-to-treat cancers
2. The machinery for recombination is part of the chromosome structure
3. Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy
4. Unique gene combinations control tropical maize response to day lengths
5. A drug combination extends survival in refractory lung cancer patients
6. Microbubble-delivered combination therapy eradicates prostate cancer in vivo
7. Combination therapy provides hope for cure of dangerous infections of cystic fibrosis patients
8. Killing drug-resistant melanoma requires combination therapy
9. Combination therapy reduced HER2-positive breast cancers
10. Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer
11. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... mechanism by which estrogen suppresses lipid synthesis in the ... approach toward treating certain liver diseases. , With ... are changing long-held views in the field. Study results ... Science Signaling . , "The dogma in the ... only receptors located in the nucleus respond to steroid ...
(Date:5/23/2013)... unnecessarily undergo surgery or harsh treatments because science ... aggressive forms of the disease. Researchers at Case ... are developing technology that allows patients to safely ... treatments or take drastic measures. , The project ... professor of biomedical engineering at Case Western Reserve ...
(Date:5/23/2013)... of the world are billions of animal and plant ... and grasses, all stacked, stored and preserved in jars ... could be critical to understanding how the Earth,s biodiversity ... footprint if only the information were easily accessible. ... the help of a team from the University of ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4
... . . Changing the behavior of a material ... the computing power of Oak Ridge National Laboratory,s Jaguar supercomputer, ... and hydrogen to nanoribbons made of boron nitride. The added ... insulator into that of a metal. That makes ...
... hot springs are furthering efforts at the Department of ... from crops such as switchgrass. The ... expensive enzymes that break down complex plant materials to ... cheaper alternative is consolidated bioprocessing, a streamlined process that ...
... study is revealing new information about a key protein,s ... neurological disorders. This work could one day lead to ... associate professor in The University of Texas at Dallas, ... with senior neuroscience student Francisco Garcia on a series ...
Cached Biology News:ORNL story tips, February 2012 2ORNL story tips, February 2012 3ORNL explores proteins in Yellowstone bacteria for biofuel inspiration 2Study looks at possible link to hyper-excitability factors in epilepsy, autism and more 2
(Date:5/24/2013)... SAN DIEGO , May 24, 2013 ... a  company using proprietary taste science technologies to discover, ... David Linemeyer , Ph.D., the Company,s ... , Vice President, Investor Relations & Corporate Communications, will ... Friday, May 31, at 10:25 a.m. Eastern Time (7:25 ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") ... science-based research and development, sales and marketing of ... announced today that it is awarding exclusive Vestiage ... of Reluma Skin Illuminating Facial Care. Qualified applicants ... sending an email to info(at)vestiageinc(dot)com and putting RELUMA ...
(Date:5/23/2013)... , May 23, 2013 Venaxis, Inc. (Nasdaq: ... focused on obtaining FDA clearance and commercializing its rapid, ... the pricing of an underwritten public offering of 10,000,000 ... purchase 3,500,000 shares of its common stock at an ... public offering price of $1.25 per share and related ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Patheon ... manufacturing services to the global pharmaceutical industry, will host ... Novel Approaches to Testing” on Tuesday, June 4, 2013 ... pharmaceutical manufacturers are required to comply with regulations for ... practices with limited scientific underpinning and little evaluation of ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
... IL-8 and Future ... in Cancer and Inflammation, COPENHAGEN, September 13 ... antibody is directed,to IL-8 (interleukin-8) and may have potential ... studies to treat glioblastoma,a cancer of the central nervous ...
... - Physicians Welcome New Option ... has a Rapidly Bactericidal Mode of Action ... treatment of both,methicillin-sensitive and resistant Staphylococcus aureus ... infections (right-sided,infective endocarditis) has been announced today ...
... Named 2007 Medical Products Industry Leader, DEERFIELD, Ill., ... announced today that it has been named 2007,Medical Products ... World) and the Dow Jones Sustainability North America Index,(DJSI ... the,company has been listed in the DJSI and the ...
Cached Biology Technology:Genmab Discloses Target and Development Plans for HuMax-Inflam 2Genmab Discloses Target and Development Plans for HuMax-Inflam 3New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 2New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 3New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 4Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year 2
Human Cell Line Slides...
... Signet offers the most comprehensive, cost-effective ... We have incorporated unprecedented quality into ... This includes proven detection chemistries and ... the TechMate protocol. It also includes ...
... 2 Detection System combines the indirect ... principle and Signets unique formulation of ... and reliablility. Signet reagents will achieve ... and automated protocols. ,Signets USA Detection ...
... Each Signet Level 2 Detection System ... avidin-biotin chemical bonding principle and Signets ... provide sensitivity, specificity and reliablility. Signet ... in both manual and automated protocols. ...
Biology Products: